GET DAILY SIGNALSEvotec (EVO) Q3 2026 Update: Revenue Holds Steady While Adjusted EBITDA Narrows Sharply
Key Takeaways
- Group revenue for the third quarter of 2026 reached €164.9 million, essentially flat compared with €163.9 million a year earlier.
- Adjusted Group EBITDA improved sharply to -€1.6 million, versus -€15.0 million in the prior-year quarter.
- Nine-month revenue declined 13.1% to €465.0 million, while nine-month adjusted EBITDA fell to -€44.3 million from -€16.9 million.
- Evotec reaffirmed its full-year 2026 guidance and said it expects revenue and adjusted EBITDA to land toward the upper end of their ranges.
- The company introduced a 2030 framework targeting roughly €1 billion in revenue, with adjusted EBITDA margins reaching 20% by the end of 2028.
Earnings Context and Why It Matters
Evotec SE, a Germany-based drug discovery and development company listed on Nasdaq through American Depositary Shares, has spent 2026 carrying out a restructuring under its "Horizon" transformation program. The company is trimming its workforce, consolidating laboratory sites, and cutting costs to reach sustainable profitability after a tough first half. These third-quarter results matter because they provide the clearest indication yet of whether those efforts are producing financial gains. I am watching closely to see whether commercial momentum in the core Discovery & Preclinical Development business and the Just – Evotec Biologics unit can offset declining revenue and move the company closer to break-even.
Reported Results
For the third quarter of 2026, Evotec reported Group revenue of €164.9 million, essentially unchanged from €163.9 million in the prior-year period. Adjusted Group EBITDA improved markedly to -€1.6 million from -€15.0 million a year earlier, a year-over-year improvement of 89.1% driven primarily by a lower cost of revenue. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
For the first nine months of 2026, Group revenue totaled €465.0 million, down 13.1% from €535.1 million. Adjusted Group EBITDA declined to -€44.3 million from -€16.9 million. The nine-month net loss widened to €195.3 million from €118.1 million, reflecting higher reorganization expenses, asset impairments, and lower revenue, partially offset by a lower cost base and a gain on the sale of Tubulis GmbH.
Segment results showed encouraging trends. Discovery & Preclinical Development revenue fell a modest 2.3% to €120.1 million in the quarter, with adjusted EBITDA improving to -€1.0 million from -€9.5 million. Just – Evotec Biologics revenue rose 9.4% to €44.8 million, and its adjusted EBITDA improved to -€0.6 million from -€5.5 million. Evotec closed the quarter with total liquidity of €400.9 million, in a net debt position.
Management reaffirmed full-year 2026 guidance of approximately €570–610 million in revenue and adjusted Group EBITDA of approximately -€105 million to -€70 million, and indicated results are tracking toward the upper end of those ranges.
Market Reaction and Investor Sentiment
Much of the third-quarter data was already signaled in preliminary figures released in mid-October, which reduced the element of surprise in the final report. Sentiment has been shaped by the company’s progress toward break-even adjusted EBITDA and the renewed visibility around its medium-term targets. At the same time, Evotec slightly tempered its long-term ambitions: the 2030 framework now targets “around” €1 billion in revenue, down from a prior goal of more than €1 billion, with adjusted EBITDA margin milestones pushed back in time. The confirmation that Vertex Pharmaceuticals selected Just – Evotec Biologics for commercial manufacturing of its investigational candidate povetacicept provided a notable positive catalyst, while the widened nine-month net loss and declining liquidity remain areas of investor caution.
Forward Outlook and Key Factors to Monitor
Evotec’s near-term trajectory hinges on whether the third quarter’s improvement is sustained. Management reaffirmed full-year 2026 guidance and pointed to results landing toward the upper end of revenue and adjusted EBITDA ranges, suggesting confidence that the Horizon cost program is taking hold. By the end of September, Evotec had already delivered more than 20% of its targeted €75 million in annual run-rate savings, ahead of plan, with roughly half of planned workforce reductions implemented.
Investors should watch whether the Discovery & Preclinical Development base business can continue converting a recovering commercial funnel into revenue growth, and whether the Vertex manufacturing selection for povetacicept matures into a meaningful revenue stream as the J.POD Redmond facility adds a third manufacturing train. The planned temporary pause in Redmond manufacturing activity during that installation could weigh on 2027 manufacturing revenue, which management says is already reflected in its plan.
Longer term, the 2030 framework outlines a path to roughly €1 billion in revenue and a 20% adjusted EBITDA margin by the end of 2028. Execution on the remaining footprint consolidation, disciplined capital allocation, and cash-flow management will be central to whether Evotec can deliver on these targets. Liquidity preservation and working-capital discipline remain key watch items as the company operates from a net debt position.
My Experience with Tickeron’s AI Tools
In my day-to-day research on biotech names like Evotec, I frequently turn to Tickeron’s AI Screener to quickly filter for technical patterns, fundamentals, and AI-driven signals. The tool helps surface comparable setups across the sector and keeps me informed on shifting market conditions without hours of manual screening. It has become a regular part of how I cross-check ideas before diving deeper into company-specific reports.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
EVO's RSI Indicator ascends from oversold territory
The RSI Indicator for EVO moved out of oversold territory on October 14, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 39 similar instances when the indicator left oversold territory. In 31 of the 39 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 26, 2026. You may want to consider a long position or call options on EVO as a result. In 62 of 100 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for EVO just turned positive on October 20, 2026. Looking at past instances where EVO's MACD turned positive, the stock continued to rise in 30 of 42 cases over the following month. The odds of a continued upward trend are 71%.
Following a +3.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVO advanced for three days, in 187 of 277 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
EVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 59 cases where EVO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for EVO entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. EVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.746) is normal, around the industry mean (7.659). EVO's P/E Ratio (476.190) is considerably higher than the industry average of (0.330). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (0.695) is also within normal values, averaging (181.047).
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric
Advertisement